Shots: Shots:

• The BT designation is based on P-I/II study assessing the safety and efficacy of mobocertinib (160mg- qd) in patients with LA/ m NSCLC- harboring EGFR exon 20 insertion mutations- prior treated with systemic CT
• The P-I/II ongoing study results: mPFS (7.3mos.); ORR (43%); safety profile was manageable. The mobocertinib development program began in the NSCLC population and is expected to expand to additional underserved populations in other tumor types
• Mobocertinib is a potent- small-molecule TKI- designed to selectively target EGFR and HER2 exon 20 insertion mutations and has received the US FDA’s ODD in 2019

Click here ­to­ read full press release/ article | Ref: Takeda  | Image: The Malaysian Reserve